Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024

GlobeNewswire05-09

Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial Data from Phase 3 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2434050907?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/C6YwZtvzo__JBt8F.ZtO3g--~B/aD0yNzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7629089790345d42d3f8b783f2c3ed55","is_english":true,"pubTime":"2024-05-09 04:05","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2434050907","market":"us","top_or_hot":-1,"title":"Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024","media":"GlobeNewswire","content":"<div>\n<p>Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial\nData from Phase 3 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crinetics-pharmaceuticals-present-advancements-atumelnant-200500103.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCrinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-05-09 04:05 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/crinetics-pharmaceuticals-present-advancements-atumelnant-200500103.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial\nData from Phase 3 ...</p>\n\n<a href=\"https://finance.yahoo.com/news/crinetics-pharmaceuticals-present-advancements-atumelnant-200500103.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0310800965.SGD","symbol_name":"FTIF - Templeton Global Balanced A Acc SGD","start_time":0,"source_url":"https://finance.yahoo.com/news/crinetics-pharmaceuticals-present-advancements-atumelnant-200500103.html","article_id":"2434050907","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/C6YwZtvzo__JBt8F.ZtO3g--~B/aD0yNzA7dz03Njg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/7629089790345d42d3f8b783f2c3ed55"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2434050907","pubTimestamp":1715198700,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial. Data from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety and Efficacy Findings. Crinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated. Additionally, data from the Phase 3 PATHFNDR-1 study of previously treated acromegaly patients who switched to paltusotine from an injected somatostatin receptor ligand, including a new analysis of patient-reported symptoms, will be presented as a poster presentation. Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled “Paltusotine: A Novel, Investigational Oral Smal","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0310800965.SGD":"FTIF - Templeton Global Balanced A Acc SGD","ENDO":"Endocan Corporation","BK4183":"个人用品","LU1267930490.SGD":"TEMPLETON GLOBAL EQUITY INCOME \"AS\" (SGD) INC A","LU0006061336.USD":"Blackrock US Small and MidCap Opportunities A2 USD","LU0211327993.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (USD) ACC","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU0211328371.USD":"TEMPLETON GLOBAL EQUITY INCOME \"A\" (MDIS) (USD)   INC","BK4175":"保健护理产品经销商","LU0889566641.SGD":"FTSF - Templeton Shariah Global Equity A Acc SGD","CAH":"卡地纳健康","BK4585":"ETF&股票定投概念","LU0792757196.USD":"TEMPLETON SHARIAH GLOBAL EQUITY FUND \"A\" (USD) ACC","LU0052756011.USD":"TEMPLETON GLOBAL BALANCED \"A\" (USD) INC","BK4139":"生物科技","LU1267930227.SGD":"TEMPLETON GLOBAL BALANCED \"AS\" (SGD) ACC A","CRNX":"Crinetics Pharmaceuticals Inc.","LU0128525689.USD":"TEMPLETON GLOBAL BALANCED \"A\"(USD) ACC","LU0310799852.SGD":"FTIF - Templeton Global Equity Income A MDIS SGD","BK4588":"碎股","LU1267930813.SGD":"FRANKLIN TEMPLETON SHARIAH GLOBAL EQUITY \"AS\" (SGD) ACC"},"translate_title":"Crinetics Pharmaceuticals将在ENDO 2024上介绍Atumelnant（CRN04894）和Paltusotine开发项目的进展","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CAH":1,"ENDO":1,"CRNX":0.9},"content_text":"Initial Data from Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia to be Presented, Along with Initial Findings from Phase 1b/2a ACTH-Dependent Cushing’s Syndrome Trial\nData from Phase 3 PATHFNDR 1 and 2 Trials of Paltusotine in Acromegaly will be Presented, in Addition to New Long-Term Safety and Efficacy Findings\nSAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced five abstracts from its clinical development programs, including four late-breaking abstracts, will be presented at the Endocrine Society’s annual meeting, ENDO 2024, taking place June 1-4, 2024 in Boston, Massachusetts.\n“This year’s Endocrine Society meeting represents a major milestone for Crinetics as we present initial findings from two clinical studies of atumelnant* (CRN04894), our investigational, once-daily oral ACTH receptor antagonist, in development for the treatment of people with classic congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, in addition to presentations featuring data from the acromegaly Phase 3 trials of our lead development candidate, paltusotine,” said Scott Struthers, Ph.D., founder and chief executive officer of Crinetics. “As we work toward submission of the new drug application for paltusotine later this year, and as our second clinical asset, atumelnant, advances through development, we are very pleased with the progress toward our vision of building the premier endocrine-focused pharmaceutical company.”\nTwo poster presentations will include clinical data for atumelnant, a novel, oral once-daily adrenocorticotropic hormone (ACTH) receptor antagonist in development for classic congenital adrenal hyperplasia (CAH) and ACTH-dependent Cushing’s syndrome. One presentation will showcase initial safety and key biomarker efficacy findings in CAH, including rapid and profound reductions in androstenedione (A4) and 17-hydroxyprogesterone levels in participants, from the Phase 2 open label TouCAHn study. A second presentation includes data from a Phase 1b/2a open-label single center study of atumelnant in ACTH-dependent Cushing’s syndrome and will feature the first evidence of rapid and sustained cortisol reductions in participants.\nCrinetics will also have a poster presentation with data from the Phase 3 PATHFNDR-2 study evaluating paltusotine in acromegaly patients who were medically untreated. Additionally, data from the Phase 3 PATHFNDR-1 study of previously treated acromegaly patients who switched to paltusotine from an injected somatostatin receptor ligand, including a new analysis of patient-reported symptoms, will be presented as a poster presentation. Data from the PATHFNDR program will be featured in a Science and Innovation Theater led by Dr. Kevin C.J. Yuen, of the Barrow Neurological Institute, on Saturday, June 1, 2024, titled “Paltusotine: A Novel, Investigational Oral Small Molecule Somatostatin Receptor Ligand for Acromegaly.” A third presentation from the paltusotine clinical program will be a poster showing long-term safety and efficacy updates from the Phase 2 ACROBAT Advance open-label extension study.\n*Proposed international nonproprietary name under review\nAdditional details on the presentations are shown below:\n\n\n\nTitle:\nOnce Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results from a 12-Week, Phase 2, Open-Label Study\n\n\nDate/Time:\nJune 3rd from 12:00 – 1:30 pm ET\n\n\nLocation:\nSession P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea - BCEC\n\n\n \n \n\n\nTitle:\nAtumelnant (CRN04894) Induces Rapid And Sustained Reductions In Serum And Urine Cortisol In Patients With ACTH-dependent Cushing Syndrome During A Phase 1b/2a, Single Center, 10-day, Inpatient, Open-label Study\n\n\nDate/Time:\nJune 3rd from 12:00 – 1:30 pm ET\n\n\nLocation:\nSession P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea - BCEC\n\n\n \n \n\n\nTitle:\nEfficacy and Safety of Once-Daily Oral Paltusotine in Medically Untreated Patients With Acromegaly: Results from the Phase 3, Randomized, Placebo-Controlled PATHFNDR-2 Study\n\n\nDate/Time:\nJune 3rd from 12:00 – 1:30 pm ET\n\n\nLocation:\nSession P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea – BCEC\n\n\n \n \n\n\nTitle:\nUse of the Acromegaly Symptom Diary (ASD) in a Phase 3, Placebo-Controlled Study of Once-Daily, Oral Paltusotine in Patients With Acromegaly Switched From Injected Octreotide or Lanreotide\n\n\nDate/Time:\nJune 3rd from 12:00pm – 1:30 pm ET\n\n\nLocation:\nNeuroendocrinology and Pituitary: Pituitary Tumors IV - ENDOExpo PosterArea - BCEC\n\n\n \n \n\n\nTitle:\nLong-Term Safety and Efficacy of Once-Daily Oral Paltusotine in the Treatment of Patients With Acromegaly: Update From ACROBAT Advance\n\n\nDate/Time:\nJune 3rd from 12:00 – 1:30 pm ET\n\n\nLocation:\nSession P108 - Late-Breaking Poster Presentations - ENDOExpo PosterArea – BCEC\n\n\n \n \n\n\n\nThe poster presentations will be made available on the Crinetics website at the time of presentation in accordance with the ENDO embargo policy.\nABOUT ATUMELNANT (CRN04894)Atumelnant, our second investigational compound, is the first once-daily, oral adrenocorticotropic hormone (ACTH) receptor antagonist that acts selectively at the melanocortin type 2 receptor (MC2R) on the adrenal glands. Diseases associated with excess ACTH can have significant impact on physical and mental health. Atumelnant has exhibited strong binding affinity for MC2R in preclinical models and has demonstrated suppression of adrenally derived glucocorticoids and androgens that are under the control of ACTH. Data in a Phase 1 healthy volunteer study demonstrated pharmacologic proof-of-concept for atumelnant, with reductions in both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations. Atumelnant is currently in Phase 2 studies for Congenital Adrenal Hyperplasia and ACTH-dependent Cushing’s syndrome.\nABOUT PALTUSOTINEPaltusotine is the first oral, once-daily selectively-targeted somatostatin receptor type 2 (SST2) agonist, and has completed its randomized, controlled Phase 3 studies for acromegaly and a Phase 2 study for carcinoid syndrome. It was designed by the Crinetics’ discovery team to provide an efficacious and convenient once-daily option for people living with acromegaly and carcinoid syndrome. In Phase 2 studies and the recently completed PATHFNDR-1 and PATHFNDR-2 Phase 3 studies, paltusotine maintained IGF-1 levels in patients with acromegaly who were switched from monthly injectable medications to paltusotine (PATHFNDR-1) and decreased IGF-1 levels in medically untreated patients (PATHFNDR-2). IGF-1 is the primary biomarker endocrinologists use to manage acromegaly patients. Results from the Phase 2 study in carcinoid syndrome further support paltusotine’s potential use beyond acromegaly.\nABOUT CRINETICS PHARMACEUTICALSCrinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and in Phase 2 clinical development for carcinoid syndrome associated with neuroendocrine tumors. Crinetics is also developing atumelnant (CRN04894), an investigational, first-in-class, oral ACTH antagonist, that is currently completing Phase 2 clinical studies for the treatment of congenital adrenal hyperplasia and Cushing’s disease. All of the company’s drug candidates are orally delivered, small molecule new chemical entities resulting from in-house drug discovery efforts, including additional discovery programs addressing a variety of endocrine conditions such as hyperparathyroidism, polycystic kidney disease, Graves’ disease, thyroid eye disease, diabetes and obesity.\nForward-Looking Statements\nThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical facts contained in this press release are forward-looking statements, including statements regarding the plans and timelines for the clinical development of atumelnant and paltusotine, including the therapeutic potential and clinical benefits or safety profile thereof; plans to submit a new drug application for paltusotine later this year; plans to develop atumelnant; and plans to present updates and findings from our research and clinical trial programs. These forward-looking statements speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions, including, without limitation, topline results that we report may change following a more comprehensive review of the data related to the clinical studies and such data may not accurately reflect the complete results of a clinical study, the possibility of unfavorable new clinical data and further analyses of existing clinical data, and the U.S. Food and Drug Administration and other regulatory authorities may not agree with our interpretation of such results; and the other risks and uncertainties described in the company’s periodic filings with the Securities and Exchange Commission (SEC). The events and circumstances reflected in the company’s forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Additional information on risks facing Crinetics can be found under the heading “Risk Factors” in Crinetics’ periodic filings with the SEC, including its annual report on Form 10-K for the year ended December 31, 2023. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by applicable law, Crinetics does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.\nContact: Corey DavisLifeSci Advisorscdavis@lifesciadvisors.com(212) 915-2577\nMedia: Natalie BadilloHead of Corporate Communicationsnbadillo@crinetics.com(858) 345-6075","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.24.0","shortVersion":"4.24.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2434050907"}